Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent

Autor: Filippo Spriano, Luca Aresu, Luciano Cascione, Giorgia Risi, Alberto J. Arribas, Sara Napoli, Andrea Rinaldi, Nicole Forster-Gross, Felix Bachmann, Marc Engelhardt, Heidi Lane, Francesco Bertoni

Microtubules are major components of the cellular cytoskeleton, ubiquitously founded in all eukaryotic cells. They are involved in mitosis, cell motility, intracellular protein and organelle transport, and maintenance of cytoskeletal shape. Avanbulin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f90da4f60761f70d012706cb310526df
https://doi.org/10.1101/2022.12.31.521730

Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study

Autor: Heidi Lane, Kristi L. Norton, Amy L. Dunn, Beth Boulden Warren, Carolyn M. Bennett, Michael Fadell, Sharon Funk, Marilyn J. Manco-Johnson, J. David Ingram, Dianne Thornhill, Amy D. Shapiro, Michael Recht, Jill Stein

Publikováno v: Blood Adv

The Joint Outcome Study (JOS), a randomized controlled trial, demonstrated that children with severe hemophilia A (HA) initiating prophylactic factor VIII (FVIII) prior to age 2.5 years had reduced joint damage at age 6 years compared with those trea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a65db6e88ff8f3367f78ac13a937e1
https://doi.org/10.1182/bloodadvances.2019001311

A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors

Autor: Silvia Stuedeli, Cristiana Sessa, Thomas Kaindl, D. Hess, Nicole Levy, Y. Metaxas, Anastasios Stathis, Patrice Larger, Heidi Lane, Roger von Moos, Peter Hafner, Mara Mantiero, Marc Engelhardt, Michael Mark, Markus Joerger, Matthias Volden

Publikováno v: Investigational New Drugs

SummaryPurpose BAL101553, the prodrug of the microtubule-destabilizer BAL27862, previously showed signs of antitumor activity when administered as a 2-h infusion, but its use was limited by vascular toxicity. We investigated an alternative dosing str

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8b1fc2bd29aa41bfe70b3c532bb7b
http://europepmc.org/articles/PMC7340672

Abstract 2575: Avanbulin, the active moiety of the tumor checkpoint controller lisavanbulin (BAL101553), has anti-lymphoma activity

Autor: Filippo Spriano, Luca Aresu, Luciano Cascione, Alberto J. Arribas, Nicole Forster-Gross, Felix Bachmann, Heidi Lane, Francesco Bertoni

Publikováno v: Cancer Research. 82:2575-2575

Background: Avanbulin (BAL27862) is a microtubule-targeting agent (MTA) that promotes tumor cell death by modulating the spindle assembly checkpoint. Preclinical studies in glioblastoma (GBM) have shown that avanbulin is also active in human cancer c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce23145f55bcd060307155a5ec78f6fb
https://doi.org/10.1158/1538-7445.am2022-2575

EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis

Autor: Raphael Berges, Dominique Figarella-Branger, Aurélie Tchoghandjian, Heidi Lane, Arnauld Sergé, Diane Braguer, Felix Bachmann, Stéphane Honoré

Publikováno v: Oncotarget
Oncotarget, 2020, 11 (8), pp.759-774. ⟨10.18632/oncotarget.27374⟩
Oncotarget, Impact journals, 2020, 11 (8), pp.759-774. ⟨10.18632/oncotarget.27374⟩

International audience; Glioblastoma (GBM) are aggressive brain tumors with limited treatment options. Cancer stem-like cells (CSLCs) contribute to GBM invasiveness, representing promising targets. BAL101553, a prodrug of BAL27862, is a novel small m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::429a452aa1fa87be3c60d5cab1aed3e6
https://hal.science/hal-03009828/document